A landmark moment has been reached for the OPTIMA-YOUNG trial! On June 26th, our very first patient was officially enrolled at the Clinique Pasteur in Brest, France, marking a major leap forward for this important clinical study.
This incredible milestone is the direct result of months of hard work, unwavering dedication, and seamless collaboration across the entire consortium. We extend a huge thank you to the exceptional team at Clinique Pasteur and to all the recruiting centres working tirelessly alongside us.
This successful enrollment officially opens the inclusion period, which is expected to run until August 2028. Over the coming months, this collective effort will continue to expand across our global network of partner sites.
Together, we are moving one step closer to answering a crucial question for premenopausal breast cancer patients: can we safely de-escalate chemotherapy without compromising outcomes?
